Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity

  • Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to -approved seizure drug, Epidiolex
  • The study will also compare DehydraTECH-CBD to generic CBD
  • EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3
  • Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents

Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://cnw.fm/iMVe3).

EPIL-A21-1, which will be conducted by a talented team that includes respirology and neurology …

Full story available on Benzinga.com

EPIL-A21-1, which will be conducted by a talented team that includes respirology and neurology …

Full story available on Benzinga.com

More Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity